Christoph U Correll – Phase III ENLIGHTEN-2 Study in Schizophrenia (Part 2)
Christoph U Correll (Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA) shares his expert insights on the rationale for combined therapy with olanzapine and samidorphan for the management of patients with schizophrenia. He also provides an overview of the key efficacy and safety findings of the recent phase III ENLIGHTEN-2 study, which evaluated weight gain with ALKS 3831 (olanzapine and samidorphan) versus olanzapine in adult subjects with schizophrenia (ClinicalTrials.gov Identifier: NCT02694328).
1. What have been the major efficacy and safety findings of the ENLIGHTEN-2 study to date? (0:08)
2. How do you expect olanzapine/samidorphan to fit into current treatment paradigms? (3:45)
See also the 1st part of this interview: Christoph U Correll – Phase III ENLIGHTEN-2 Study in Schizophrenia (Part 1)
Disclosures: Prof. Correll has been a consultant and/or advisor to or has received honoraria from: Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, Gerson Lehrman Group, Indivior, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Merck, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda and Teva; he has provided expert testimony for Janssen and Otsuka; he has served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus and Teva; he has received grant support from Janssen and Takeda; and he is also a stock option holder of LB Pharma.
Support: Interview and filming supported by Touch Medical Media.
Share this Video
Related Videos In Psychiatric Disorders
Barriers when implementing positive psychiatry interventions: Erick Messias, APA 2023
Implementing positive psychiatry approaches can face various barriers across different levels of care. These include resistance to change, limited resources, time constraints, and the dominance of a deficit-focused model. In this touchNEUROLOGY interview, we speak with Dr Erick Messias (Saint Louis University School of Medicine, St. Louis, MO, USA) to discuss how to address these […]
Five approaches of positive psychiatry, engaging with policy makers: Erick Messias, APA 2023
Positive psychiatry encompasses several approaches that focus on promoting well-being and resilience in mental health care. In this touchNEUROLOGY interview, we speak with Dr Erick Messias (Saint Louis University School of Medicine, St. Louis, MO, USA) to discuss how positive psychiatry can be effectively integrated into clinical practice to manage patient outcomes and well-being, and […]
Discovery of ketamine to treat psychiatric disorders targeting monoamine signaling: John Krystal, APA 2023
The discovery of ketamine’s therapeutic potential for psychiatric disorders changed the field of mental health, since nearly every FDA-approved medication for schizophrenia and mood disorders targeted monoamine signaling, i.e., dopamine, serotonin, and norepinephrine. As ketamine was initially used as an anaesthetic, ketamine’s ability to modulate monoamine signaling pathways emerged, leading to ground-breaking breakthroughs. In this […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!